InterHealth acquires Next Pharmaceuticals

InterHealth acquires Next Pharmaceuticals

Brands acquired from Next Pharmaceuticals include Relora, Sytrinol, Seditol and Nexrutine.

InterHealth Nutraceuticals Inc., a leading researcher, developer and marketer of branded nutraceutical ingredients, announced that it has acquired the assets of Next Pharmaceuticals, a Salinas, Calif.-based raw material dietary supplement supplier. Brands acquired from Next Pharmaceuticals include Relora®, Sytrinol®, Seditol® and Nexrutine®. Relora® and Sytrinol® are the leading brand from this acquisition. Relora® is a leading natural dietary supplement ingredient that helps support healthy stress and weight levels. Sytrinol® is a patented blend of flavones and tocotrienols for heart health.

“The acquisition of the Next Pharmaceuticals’ brands, and in particular, the Relora® and Sytrinol® brands, provides InterHealth with increased market share in the weight-management and cardiovascular categories. The product line represents InterHealth’s introduction into the mood category. Next Pharmaceuticals has built best-in-class brands, which fit nicely in the InterHealth brand portfolio,” commented Paul Dijkstra, president and CEO of InterHealth.

The transaction marks the third acquisition completed by InterHealth since its acquisition by Kainos Capital in November 2013. InterHealth acquired Chick Cart manufacturing facility March 2014 and the brand 7-Keto® from Humanetics August 2014.

InterHealth offers branded, scientifically backed ingredients that help support consumers’ health and well-being. InterHealth is committed to clinical research and offering the highest quality branded ingredients available.


Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.